Beam Therapeutics Future Growth
Future criteria checks 2/6
Beam Therapeutics is forecast to grow earnings and revenue by 2.5% and 38.8% per annum respectively. EPS is expected to grow by 7.5% per annum. Return on equity is forecast to be -99.1% in 3 years.
Key information
2.5%
Earnings growth rate
7.54%
EPS growth rate
| Biotechs earnings growth | 24.0% |
| Revenue growth rate | 38.8% |
| Future return on equity | -99.11% |
| Analyst coverage | Good |
| Last updated | 08 May 2025 |
Recent future growth updates
Recent updates
Advancing BEAM-101 And BEAM-302 Will Transform Treatment Of Hematology And Liver Genetic Diseases
Mar 22 Promising programs in genetic diseases and innovative technology could significantly boost market share and revenue potential.Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy
Mar 21Beam Therapeutics: Single-Base Editing Seems To Work
Mar 10Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares
Jan 31
Beam Therapeutics: Too Expensive For Me, But Watch For Important Catalysts
Jan 22Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Dec 20Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch
Nov 07Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price
Oct 28Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy
Sep 29We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
Sep 04Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares
Jul 12Beam Therapeutics: Slow Developmental Progress, But Promising Potential
Jul 01We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
May 13Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
Apr 24Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S
Apr 07Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 01Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade
Feb 29Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now
Feb 08This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year
Nov 01We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely
Jul 23Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Apr 08Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts
Nov 08Beam Therapeutics: Now Is Not The Right Time To Own
Sep 15Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M
Aug 09Beam drops 19% as FDA issues clinical hold on blood cancer candidate
Aug 01Revisiting Beam Therapeutics Among Collaborative Catalysts
Jul 10Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 48 | -508 | -295 | -312 | 7 |
| 12/31/2026 | 55 | -458 | -333 | -304 | 14 |
| 12/31/2025 | 56 | -423 | -342 | -279 | 15 |
| 3/31/2025 | 64 | -387 | -361 | -351 | N/A |
| 12/31/2024 | 64 | -377 | -356 | -347 | N/A |
| 9/30/2024 | 350 | -144 | -145 | -136 | N/A |
| 6/30/2024 | 353 | -143 | -153 | -137 | N/A |
| 3/31/2024 | 361 | -135 | -169 | -139 | N/A |
| 12/31/2023 | 378 | -133 | -183 | -149 | N/A |
| 9/30/2023 | 82 | -314 | -392 | -353 | N/A |
| 6/30/2023 | 80 | -327 | -380 | -338 | N/A |
| 3/31/2023 | 77 | -316 | -353 | -306 | N/A |
| 12/31/2022 | 61 | -289 | -26 | 23 | N/A |
| 9/30/2022 | 92 | -315 | 39 | 94 | N/A |
| 6/30/2022 | 77 | -234 | 123 | 171 | N/A |
| 3/31/2022 | 60 | -238 | 148 | 191 | N/A |
| 12/31/2021 | 52 | -371 | -113 | -66 | N/A |
| 9/30/2021 | 1 | -401 | -134 | -92 | N/A |
| 6/30/2021 | 0 | -408 | -155 | -117 | N/A |
| 3/31/2021 | 0 | -366 | -132 | -107 | N/A |
| 12/31/2020 | 0 | -196 | -112 | -96 | N/A |
| 9/30/2020 | 0 | -132 | -100 | -89 | N/A |
| 6/30/2020 | 0 | -119 | -94 | -85 | N/A |
| 3/31/2020 | 0 | -106 | -87 | -74 | N/A |
| 12/31/2019 | 0 | -91 | -85 | -72 | N/A |
| 9/30/2019 | 0 | -86 | -79 | -57 | N/A |
| 6/30/2019 | 0 | -134 | -70 | -50 | N/A |
| 3/31/2019 | N/A | -124 | -57 | -42 | N/A |
| 12/31/2018 | N/A | -117 | N/A | -20 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BEAM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BEAM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BEAM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BEAM's revenue (38.8% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: BEAM's revenue (38.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BEAM is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/12 07:51 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beam Therapeutics Inc. is covered by 23 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Alec Stranahan | BofA Global Research |